ArticleClinical, cosmetic and investigational dermatology2009
Biologics in the management of psoriasis.
Article in Clinical, cosmetic and investigational dermatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Psychological Comorbidities in Palmoplantar Psoriasis and Psoriatic Arthritis: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Impact of isoflavone genistein on psoriasis in in vivo and in vitro investigations.Scientific reports · 2021Trial
- Drug survival of biologic treatments for psoriasis and psoriatic arthritis in Denmark, 2018-23: a nationwide register-based cohort study.Skin health and disease · 2026Article
- Long-term postmarketing safety of psoriasis treatments on autoimmune disease risk: a 15-year nationwide cohort study in Denmark.Skin health and disease · 2026Article
- Post-Marketing Safety of Ustekinumab Based on 14-Year Follow-Up in Danish National Patient Data.Pharmacoepidemiology and drug safety · 2024Article
- Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses.Dermatology and therapy · 2024Review
- Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis.Life (Basel, Switzerland) · 2021Review
- Uncovering the unmet needs among psoriasis patients in the Asia-Pacific region.The Journal of dermatology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic inflammatory systemic disease for which there exist topical, ultraviolet, systemic, and biologic treatments. Biologic agents selectively interfere with the immune mechanisms responsible for psoriasis. Etanercept, infliximab, and adalimumab target tumor necrosis factor-alpha and have demonstrated efficacy in the treatment of psoriasis and psoriatic arthritis. Alefacept and efalizumab target T lymphocytes, are effective in the treatment of psoriasis, but are not approved for psoriatic arthritis. Finally, ustekinumab and ABT-874 target interleukin-12 and interleukin-23, and they have demonstrated efficacy in the treatment of psoriasis. The objective of this review is to present efficacy and safety data from randomized controlled trials of the biologic agents in the treatment of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.